---
title: Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki.
nct_id: NCT04560465
overall_status: COMPLETED
phase: PHASE2
sponsor: Alex Ekwueme Federal University Teaching Hospital
study_type: INTERVENTIONAL
primary_condition: To Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During Myomectomy
countries: Nigeria
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04560465.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04560465"
ct_last_update_post_date: 2020-09-23
last_seen_at: "2026-05-12T07:17:56.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki.

**Official Title:** Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki

**NCT ID:** [NCT04560465](https://clinicaltrials.gov/study/NCT04560465)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 59
- **Lead Sponsor:** Alex Ekwueme Federal University Teaching Hospital
- **Conditions:** To Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During Myomectomy
- **Start Date:** 2018-06-01
- **Completion Date:** 2019-06-01
- **CT.gov Last Update:** 2020-09-23

## Brief Summary

to determine safety and efficacy of Tranexamic Acid in reducing blood loss during Myomectomy in our institution.

## Detailed Description

A double blinded randomized controlled trial in which cases were given 1000mg intravenous tranexamic acid into 1L of intravenous normal saline and control were given 10mls of placebo water for injection into same amount of intravenous fluid. outcome of both groups in terms of intraoperative blood loss, duration of surgery, postoperative packed cell volume and total blood loss with risk of blood transfusion were then determined.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 50 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* non-pregnant women with symptomatic myomas women with no known contraindication to tranexamic acid

Exclusion Criteria:

* past history of thromboembolic disorder, ischaemic heart disease, malignancy or liver disease
```

## Arms

- **group A: Cases that had tranexamic acid infusion** (EXPERIMENTAL) — Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
- **Group B: Control** (PLACEBO_COMPARATOR) — control were given perioperative placebo at the rate of 100mls per hour

## Interventions

- **Tranexamic acid** (DRUG) — intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control

## Primary Outcomes

- **Average duration of surgery in each group** _(time frame: one year)_ — Average duration of Surgeries were calculated for each group
- **Mean intraoperative Blood loss** _(time frame: one year)_ — The mean intraoperative blood loss was calculated for both groups
- **Postoperative Haemoglobin concentration** _(time frame: one year)_ — Average Postoperative Haemoglobin concentration of both groups were determined

## Secondary Outcomes

- **Blood Transfusion** _(time frame: One year)_

## Locations (1)

- AEFUTHA, Abakaliki, Ebonyi State, Nigeria

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.aefutha|abakaliki|ebonyi state|nigeria` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04560465.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04560465*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*